Abstract:Importance: An end-to-end efficacy evaluation approach for identifying progression risk after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with stage IV EGFR variant-positive non-small cell lung cancer (NSCLC) is lacking. Objective: To propose a clinically applicable large-scale bidirectional generative adversarial network for predicting the efficacy of EGFR-TKI therapy in patients with NSCLC. Design, setting, and participants: This diagnostic/prognostic study enrolled 465 patients from January 1, 2010, to August 1, 2017, with follow-up from February 1, 2010, to June 1, 2020. A deep learning (DL) semantic signature to predict progression-free survival (PFS) was constructed in the training cohort, validated in 2 external validation and 2 control cohorts, and compared with the radiomics signature. Exposures: An end-to-end bidirectional generative adversarial network framework was designed to predict the progression risk in patients with NSCLC. Main outcomes and measures: The primary end point was PFS, considering the time from the initiation of therapy to the date of recurrence, confirmed disease progression, or death. Results: A total of 342 patients with stage IV EGFR variant-positive NSCLC receiving EGFR-TKI therapy met the inclusion criteria. Of these, 145 patients from 2 of the hospitals (n = 117 and 28) formed a training cohort (mean [SD] age, 61 [11] years; 87 [60.0%] female), and the patients from 2 other hospitals comprised 2 external validation cohorts (validation cohort 1: n = 101; mean [SD] age, 57 [12] years; 60 [59.4%] female; and validation cohort 2: n = 96, mean [SD] age, 58 [9] years; 55 [57.3%] female). Fifty-six patients with advanced-stage EGFR variant-positive NSCLC (mean [SD] age, 52 [11] years; 26 [46.4%] female) and 67 patients with advanced-stage EGFR wild-type NSCLC (mean [SD] age, 54 [10] years; 10 [15.0%] female) who received first-line chemotherapy were included. A total of 90 (26%) receiving EGFR-TKI therapy with a high risk of rapid disease progression were identified (median [range] PFS, 7.3 [1.4-32.0] months in the training cohort, 5.0 [0.6-34.6] months in validation cohort 1, and 6.4 [1.8-20.1] months, in validation cohort 2) using the DL semantic signature.The PFS decreased by 36% (hazard ratio, 2.13; 95% CI, 1.30-3.49; P < .001) compared with that in other patients (median [range] PFS, 11.5 [1.5-64.2] months in the training cohort, 10.9 [1.1-50.5] in validation cohort 1, and 8.9 [0.8-40.6] months in validation cohort 2. No significant differences were observed when comparing the PFS of high-risk patients receiving EGFR-TKI therapy with the chemotherapy cohorts (median PFS, 6.9 vs 4.4 months; P = .08). In terms of predicting the tumor progression risk after EGFR-TKI therapy, clinical decisions based on the DL semantic signature led to better survival outcomes than those based on radiomics signature across all risk probabilities by the decision curve analysis. Conclusions and relevance: This diagnostic/prognostic study provides a clinically applicable approach for identifying patients with stage IV EGFR variant-positive NSCLC who are not likely to benefit from EGFR-TKI therapy. The end-to-end DL-derived semantic features eliminated all manual interventions required while using previous radiomics methods and have a better prognostic performance.

Development and Validation of a Radiomics Nomogram for Progression-Free Survival Prediction in Stage IV EGFR-mutant Non-Small Cell Lung Cancer.

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Prognostic Value of a CT Radiomics-Based Nomogram for the Overall Survival of Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy.

Delta Radiomics Model for the Prediction of Progression-Free Survival Time in Advanced Non-Small-cell Lung Cancer Patients after Immunotherapy.

Establishment of prognostic nomograms for predicting the progression free survival of EGFR ‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy

Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations

The Potential Of Radiomics Nomogram In Non-Invasively Prediction Of Epidermal Growth Factor Receptor Mutation Status And Subtypes In Lung Adenocarcinoma

Development and Validation of a Radiomics Nomogram Based on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Clinicopathological Factors to Predict the Survival Outcomes of Patients With Non-Small Cell Lung Cancer

A Nomogram for Predicting the Risk of Lymph Node Metastasis in T1–2 Non-Small-cell Lung Cancer Based on PET/CT and Clinical Characteristics

Habitat radiomics and deep learning fusion nomogram to predict EGFR mutation status in stage I non-small cell lung cancer: a multicenter study

Development of a Nomogram Based on 3D CT Radiomics Signature to Predict the Mutation Status of EGFR Molecular Subtypes in Lung Adenocarcinoma: A Multicenter Study

Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

Computed tomography-based radiomics and clinical-genetic features for brain metastasis prediction in patients with stage III/IV epidermal growth factor receptor-mutant non-small-cell lung cancer

Nomograms for Predicting Disease Progression in Patients of Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy

Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer

Nomogram Based on Preoperative CT Imaging Predicts the EGFR Mutation Status in Lung Adenocarcinoma

Development and Validation of a CT-Based Radiomics Nomogram for Predicting Postoperative Progression-Free Survival in Stage I–III Renal Cell Carcinoma

Prognostic nomogram combining 18F-FDG PET/CT radiomics and clinical data for stage III NSCLC survival prediction

Dual‐Phase Enhanced CT‐Derived Radiomics Nomogram for Progression‐Free Survival Prediction in Stage IV Lung Adenocarcinoma